Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk M
Go back to Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk M| Geron Corp (NASDAQ: GERN) | Delayed: 1.57 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.57 | 52 Week High | $5.30 | |||
| Open | $1.57 | 52 Week Low | $1.81 | |||
| Day High | $1.57 | P/E | N/A | |||
| Day Low | $1.57 | EPS | $-0.35 | |||
| Volume | 2,380 | |||||
